Berger Financial Group Inc grew its position in shares of Chemed Co. (NYSE:CHE – Free Report) by 5.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 472 shares of the company’s stock after acquiring an additional 25 shares during the quarter. Berger Financial Group Inc’s holdings in Chemed were worth $256,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of CHE. Legacy Capital Wealth Partners LLC bought a new stake in shares of Chemed in the 1st quarter worth about $581,000. Parallel Advisors LLC increased its stake in Chemed by 24.1% during the second quarter. Parallel Advisors LLC now owns 962 shares of the company’s stock worth $521,000 after acquiring an additional 187 shares during the last quarter. AGF Management Ltd. purchased a new stake in Chemed during the first quarter valued at approximately $3,618,000. Pitcairn Co. lifted its stake in shares of Chemed by 2.4% in the 1st quarter. Pitcairn Co. now owns 1,046 shares of the company’s stock valued at $562,000 after purchasing an additional 25 shares during the last quarter. Finally, Bailard Inc. boosted its holdings in shares of Chemed by 7.5% in the 2nd quarter. Bailard Inc. now owns 2,473 shares of the company’s stock worth $1,340,000 after purchasing an additional 173 shares during the period. 94.25% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the company. StockNews.com began coverage on Chemed in a report on Thursday, October 5th. They set a “buy” rating on the stock. Royal Bank of Canada increased their target price on shares of Chemed from $576.00 to $604.00 and gave the company an “outperform” rating in a research note on Monday, October 30th.
Chemed Price Performance
Shares of NYSE:CHE opened at $578.59 on Thursday. The firm has a market capitalization of $8.71 billion, a PE ratio of 35.81, a price-to-earnings-growth ratio of 3.39 and a beta of 0.49. The business has a 50 day simple moving average of $530.80 and a two-hundred day simple moving average of $532.08. Chemed Co. has a 1 year low of $481.99 and a 1 year high of $590.58.
Chemed (NYSE:CHE – Get Free Report) last posted its quarterly earnings data on Wednesday, October 25th. The company reported $5.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.92 by $0.40. The company had revenue of $564.53 million during the quarter, compared to analysts’ expectations of $558.42 million. Chemed had a return on equity of 32.87% and a net margin of 10.99%. Chemed’s revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.74 EPS. Equities research analysts expect that Chemed Co. will post 19.3 EPS for the current fiscal year.
Chemed Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, December 4th. Stockholders of record on Monday, November 13th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date is Friday, November 10th. Chemed’s payout ratio is presently 9.91%.
Insider Buying and Selling
In other Chemed news, CFO David Patrick Williams sold 3,814 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $586.32, for a total value of $2,236,224.48. Following the completion of the sale, the chief financial officer now directly owns 7,012 shares of the company’s stock, valued at approximately $4,111,275.84. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Kevin J. Mcnamara sold 5,000 shares of the stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $560.68, for a total transaction of $2,803,400.00. Following the transaction, the chief executive officer now owns 112,968 shares of the company’s stock, valued at approximately $63,338,898.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO David Patrick Williams sold 3,814 shares of Chemed stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $586.32, for a total value of $2,236,224.48. Following the completion of the sale, the chief financial officer now owns 7,012 shares of the company’s stock, valued at $4,111,275.84. The disclosure for this sale can be found here. Insiders have sold 21,031 shares of company stock valued at $12,157,220 in the last 90 days. Company insiders own 4.03% of the company’s stock.
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
- Five stocks we like better than Chemed
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Is it time to buy the dip in Walmart shares?
- Trading Halts Explained
- Unlocking AI investment opportunities in healthcare
- Best Stocks Under $5.00
- New Disney investor propels stock to ranks of best S&P gainers
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.